Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience

Yilmaz U., Yilmaz U., Yasar Z., Kirakli E. K., Ulger S., Ozdogan Y., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.12, sa.1, ss.334-339, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.4103/0973-1482.163682
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.334-339
  • Anahtar Kelimeler: Concurrent chemoradiotherapy, nonsmall cell lung cancer, Stage III, survival, CONCURRENT THORACIC RADIOTHERAPY, THERAPY ONCOLOGY GROUP, RANDOMIZED PHASE-II, RADIATION-THERAPY, INDUCTION CHEMOTHERAPY, CONCOMITANT CHEMORADIOTHERAPY, SEQUENTIAL CHEMORADIOTHERAPY, ORAL VINORELBINE, CISPLATIN, TRIAL
  • Ankara Üniversitesi Adresli: Evet

Özet

Aim: Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent CRT in unresectable Stage III NSCLC in Turkey.